Updated Oncodetect Blood Test Targets Cancer Recurrence
The upgraded test monitors 5,000 genetic markers to help adults with solid tumors detect potential cancer recurrence earlier.
Updated on Oct. 31, 2026 in Cancer
Live Poll
Is now a good time for patients to prioritize advanced molecular cancer screening in their healthcare?
Abbott has launched an updated version of its Oncodetect blood test capable of identifying up to 5,000 genetic markers. The test aims to help clinicians detect molecular signs of cancer recurrence in patients with solid tumors.
Why it matters
This development offers a more comprehensive way to monitor for cancer remnants after treatment by analyzing tumor-specific DNA in the blood. It provides a non-invasive tool to help doctors identify potential recurrence earlier in the estimated 3 million U.S. patients with solid tumors.
Clinical testing showed the updated test successfully identified 90% of triple-negative breast cancer patients who experienced recurrence and detected molecular signs before recurrence in 14 esophageal cancer patients. Over 20 ongoing studies are currently evaluating the test's efficacy across various tumor types.
The players
Abbott
A global healthcare company that develops diagnostics, medical devices, and nutritional products.
The details
The updated Oncodetect test functions by first analyzing a patient's initial tumor sample to identify unique DNA markers specific to their cancer. Once these markers are cataloged, the test scans the patient's blood for the presence of these same tumor-specific DNA signatures. By increasing the capacity from 200 to 5,000 genetic markers, the system is designed to catch more subtle molecular indicators of residual or returning disease.
Timeline
Abbott acquired the test developer in March 2026.
The SimpleScreen blood test launched in September 2026.
The updated Oncodetect test launched on October 26, 2026.
Health Landscape
This launch reflects the ongoing industry shift toward high-sensitivity liquid biopsies that monitor circulating tumor DNA. It represents a significant evolution in oncology, moving beyond general screening toward highly personalized, marker-specific surveillance of solid tumors.
Patients with solid tumors should discuss with their oncologist whether molecular blood-based monitoring is appropriate for their specific diagnosis. Understanding the utility of such tests is a conversation to have with your care team to determine how this surveillance fits into your existing follow-up schedule.
The takeaway
Early detection of cancer recurrence through blood-based genetic markers is an active and evolving field of medicine. Ask your physician about the clinical standards for post-treatment monitoring and what specific tests are appropriate for your individual health history and cancer type.
Further reading
For more information on the current state of diagnostic innovation, visit Cancer.
Source note: This article includes information reported by Winona Daily News.
Live Poll
Is now a good time for patients to prioritize advanced molecular cancer screening in their healthcare?
